Patents by Inventor Joseph S. Takahashi

Joseph S. Takahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180296523
    Abstract: Disclosed are methods comprising administering to a mammal suffering from, or at risk of suffering from, a clock-controlled disorder, such as metabolic syndrome or a constituent condition thereof, a composition comprising at least one polymethoxylated flavone. Disclosed are methods comprising administering a composition comprising at least one polymethoxylated flavone to a mammal suffering from or at risk of suffering from a sleep disorder; suffering from aging; and/or suffering from or at risk of suffering from a mood disorder. The polymethoxylated flavone may be nobiletin and/or tangeretin. The composition may also comprise other compounds, such as nicotinamide riboside and/or pterostilbene, and/or other compounds expected to improve one or more symptoms of metabolic syndrome, a sleep disorder, a mood disorder, aging, a cardiovascular disease, an immune disorder, a neurodegenerative disease, and/or a cancer.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 18, 2018
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zheng Chen, Seung-Hee Yoo, Joseph S. Takahashi
  • Publication number: 20120232003
    Abstract: The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention.
    Type: Application
    Filed: March 15, 2010
    Publication date: September 13, 2012
    Inventors: Joseph S. Takahashi, Steve A. Kay
  • Patent number: 6476188
    Abstract: The present invention discloses the identity of the first enzyme that has been demonstrated to be involved in maintaining circadian rhythms. This enzyme, the Drosophila DOUBLETIME protein is also shown to be an ortholog of human casein kinase-1&egr;. In addition, a variant of this enzyme is shown to be cause of the hamster tau mutant phenotype. Thus the present invention also relates to variants of DOUBLETIME, and their nucleic acid and amino acid sequences. The present invention further provides methods of using these variants in drug assays and diagnostics.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: November 5, 2002
    Assignees: The Rockefeller University, Northwestern University
    Inventors: Michael W. Young, Brian Kloss, Justin Blau, Jeffrey Price, Joseph S. Takahashi, Phillip L. Lowrey
  • Patent number: 5874241
    Abstract: The present invention provides isolated and purified polypeptide components of the mammalian circadian clock, polynucleotides that encode those polypeptides, expression vectors containing those polynucleotides, host cells transformed with those expression vectors, a process of making the polypeptide components using those polynucleotides and vectors, and processes using those polypeptides and polynucleotides.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: February 23, 1999
    Assignee: Northwestern University
    Inventors: Joseph S. Takahashi, Fred W. Turek, Lawrence H. Pinto